CY1113343T1 - hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ - Google Patents

hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ

Info

Publication number
CY1113343T1
CY1113343T1 CY20121101096T CY121101096T CY1113343T1 CY 1113343 T1 CY1113343 T1 CY 1113343T1 CY 20121101096 T CY20121101096 T CY 20121101096T CY 121101096 T CY121101096 T CY 121101096T CY 1113343 T1 CY1113343 T1 CY 1113343T1
Authority
CY
Cyprus
Prior art keywords
sport
fractures
reduce
vertebral fractures
hpth
Prior art date
Application number
CY20121101096T
Other languages
English (en)
Inventor
Janet M Hock
Gregory A Gaich
Willard H Dere
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113343(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06027055A external-priority patent/EP1769804B1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113343T1 publication Critical patent/CY1113343T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Η εφεύρεση αφορά σε μία μέθοδο για την αύξηση της σκληρότητας και/ή της ακαμψίας των οστών και/ή την μείωση της πιθανότητας και/ή της σοβαρότητας κατάγματος των οστών με την χορήγηση παραθυρεοειδικής ορμόνης. Η μέθοδος μπορεί να χρησιμοποιηθεί για την αύξηση της σκληρότητας ή της ακαμψίας των οστών σε μία θέση ενός εν δυνάμει ή πραγματικού τραύματος, όπως στο ισχίο ή στην σπονδυλική στήλη ενός ατόμου σε κίνδυνο ή που πάσχει από οστεοπόρωση. Η μέθοδος της εφεύρεσης μπορεί να μειώσει την συχνότητα σπονδυλικού κατάγματος, να μειώσει την συχνότητα πολλαπλών σπονδυλικών καταγμάτων, να μειώσει την σοβαρότητα σπονδυλικού κατάγματος, και/ή να μειώσει την συχνότητα μη σπονδυλικού κατάγματος.
CY20121101096T 1998-08-19 2012-11-14 hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ CY1113343T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
EP06027055A EP1769804B1 (en) 1998-08-19 1999-08-19 hPTH(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human

Publications (1)

Publication Number Publication Date
CY1113343T1 true CY1113343T1 (el) 2016-06-22

Family

ID=26792729

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121101096T CY1113343T1 (el) 1998-08-19 2012-11-14 hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ
CY20171101077T CY1119552T1 (el) 1998-08-19 2017-10-13 Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171101077T CY1119552T1 (el) 1998-08-19 2017-10-13 Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων

Country Status (33)

Country Link
US (2) US6977077B1 (el)
EP (3) EP2266598B1 (el)
JP (5) JP2002523375A (el)
KR (1) KR100454207B1 (el)
CN (1) CN1205997C (el)
AR (1) AR033639A1 (el)
AT (1) ATE231000T1 (el)
AU (1) AU746277B2 (el)
BR (1) BR9909445A (el)
CA (1) CA2325371C (el)
CO (1) CO5130020A1 (el)
CY (2) CY1113343T1 (el)
CZ (1) CZ301017B6 (el)
DE (2) DE15152726T1 (el)
DK (4) DK2907522T3 (el)
DZ (1) DZ2873A1 (el)
EA (1) EA003362B1 (el)
ES (4) ES2393200T3 (el)
HK (3) HK1030545A1 (el)
HR (1) HRP20000755A2 (el)
HU (2) HU230697B1 (el)
ID (1) ID29039A (el)
IL (2) IL138829A0 (el)
MY (1) MY129227A (el)
NO (2) NO323984B1 (el)
NZ (1) NZ507056A (el)
PE (1) PE20001089A1 (el)
PL (1) PL201688B1 (el)
PT (4) PT1769804E (el)
TR (1) TR200003455T2 (el)
TW (1) TW576747B (el)
UA (1) UA72205C2 (el)
WO (1) WO2000010596A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1531855A4 (en) 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
MXPA06003064A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y hormona paratiroide.
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
KR20170089018A (ko) 2009-09-09 2017-08-02 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 pth가 주 1회 투여되는 것을 특징으로 하는, pth 함유 골다공증 치료/예방제
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 pth 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
ATE238043T1 (de) * 1994-12-22 2003-05-15 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
HU226866B1 (en) * 1997-09-09 2009-12-28 Hoffmann La Roche Fracture healing using pthrp analogs
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
DK1769804T3 (da) 2012-10-15
HK1212602A1 (zh) 2016-06-17
UA72205C2 (uk) 2005-02-15
US20050197294A1 (en) 2005-09-08
NO323984B1 (no) 2007-07-30
BR9909445A (pt) 2000-12-12
HU230697B1 (hu) 2017-09-28
DK2907522T3 (en) 2017-10-23
ID29039A (id) 2001-07-26
KR100454207B1 (ko) 2004-10-26
JP2017190332A (ja) 2017-10-19
PT1769804E (pt) 2012-11-13
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
US7163684B2 (en) 2007-01-16
EA200001015A1 (ru) 2001-02-26
HUP0101594A3 (en) 2002-01-28
CA2325371C (en) 2004-08-17
PL201688B1 (pl) 2009-04-30
NO20005947L (no) 2000-11-24
DK2266598T3 (en) 2017-05-15
CZ301017B6 (cs) 2009-10-14
DE69904918T2 (de) 2003-11-13
EP1059933B1 (en) 2003-01-15
JP2011021035A (ja) 2011-02-03
DE69904918D1 (de) 2003-02-20
EP2907522B1 (en) 2017-08-02
ATE231000T1 (de) 2003-02-15
TR200003455T2 (tr) 2001-06-21
CN1308545A (zh) 2001-08-15
DZ2873A1 (fr) 2003-12-15
HK1030545A1 (en) 2001-05-11
NO20072983L (no) 2000-11-24
ES2190244T3 (es) 2003-07-16
NO20005947D0 (no) 2000-11-24
PT1059933E (pt) 2003-06-30
CZ20004134A3 (cs) 2001-08-15
PE20001089A1 (es) 2000-11-04
ES2549551T3 (es) 2017-11-27
DE15152726T1 (de) 2015-12-10
TW576747B (en) 2004-02-21
JP2015028065A (ja) 2015-02-12
WO2000010596A1 (en) 2000-03-02
HU1200430D0 (hu) 2001-11-28
AR033639A1 (es) 2004-01-07
JP2014139220A (ja) 2014-07-31
ES2549551T1 (es) 2015-10-29
EP1059933A1 (en) 2000-12-20
AU5575099A (en) 2000-03-14
CO5130020A1 (es) 2002-02-27
MY129227A (en) 2007-03-30
NZ507056A (en) 2003-10-31
IL138829A (en) 2011-01-31
EA003362B1 (ru) 2003-04-24
PT2907522T (pt) 2017-10-23
HRP20000755A2 (en) 2001-02-28
ES2621653T3 (es) 2017-07-04
PL343595A1 (en) 2001-08-27
JP6177718B2 (ja) 2017-08-09
KR20010072763A (ko) 2001-07-31
HUP0101594A2 (hu) 2001-11-28
CN1205997C (zh) 2005-06-15
HK1102496A1 (en) 2007-11-23
IL138829A0 (en) 2001-10-31
ES2393200T3 (es) 2012-12-19
CA2325371A1 (en) 2000-03-02
PT2266598T (pt) 2017-05-02
EP2266598B1 (en) 2017-02-22
CY1119552T1 (el) 2018-03-07
DK2907522T1 (da) 2015-10-19
EP2266598A1 (en) 2010-12-29
EP2907522A1 (en) 2015-08-19
US6977077B1 (en) 2005-12-20
DK1059933T3 (da) 2003-04-07

Similar Documents

Publication Publication Date Title
CY1113343T1 (el) hPTH(1-34) ΓΙΑ ΧΡΗΣΗ ΣΕ ΠΡΟΛΗΨΗ Ή ΜΕΙΩΣΗ ΤΗΣ ΣΥΧΝΟΤΗΤΑΣ Ή ΣΟΒΑΡΟΤΗΤΑΣ ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΙ/Ή ΜΗ-ΣΠΟΝΔΥΛΙΚΩΝ ΚΑΤΑΓΜΑΤΩΝ ΣΕ ΕΝΑΝ ΑΝΤΡΑ
EP1205154A3 (en) Osteosynthesis plating apparatus and method with extension plate
TW200513230A (en) Bone fixing equipment
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
FR2827500B1 (fr) Plaque d'osteosynthese de l'extremite superieure de l'humerus
DK1663037T3 (da) Ortopædisk implantat og knogleskruesamling
DE69918848D1 (de) Vorderseitenplatte für lendenwirbel und positionierwerkzeug dafür
ZA200409570B (en) Intramedullary fixation device for metaphyseal long bone fractures.
FI974368A (fi) Kasvuhormonin vapautumista edistäviä dipeptidejä
CA2495110A1 (en) Method and apparatus for repairing the mid-foot region via an intramedullary nail
ATE148328T1 (de) Knochenchirurgische haltevorrichtung
WO2006007553A3 (en) Fixation elements
ATE253554T1 (de) 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon
WO2005013947A3 (en) Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
DE50302686D1 (en) System für die osteosynthese
CY1118882T1 (el) Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων
SE0101585L (sv) Implantat för att fixera benfragment vid femurfrakturer
EP1295605A3 (en) Method of increasing bone toughness and stiffness and reducing fractures
Khateeb et al. Comparative study between dynamic hip screw and plate with proximal femoral nailing in trochanteric fractures of femur
MX2022001931A (es) Placa para unir temporalmente los fragmentos de una fractura.
MD1680G2 (ro) Metodă de determinare a localizării fracturii oaselor nazale şi dispozitiv de realizare a ei
PL379163A1 (pl) Urządzenie do stabilizacji kości, zwłaszcza krętarza
WO2005087809A3 (en) Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion
UA32147A (uk) Спосіб профілактики вторинних деформацій носа при вроджених та набутих незрощеннях верхньої губи
UA34192A (uk) Спосіб остеосинтезу фрагментів довгих кісток та пристрій для його здійснення